Companies / TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
Nasdaq: TCRXCIK 1783328WALTHAM, MA
Financials · FY2025
Ownership
67.8M shares outstanding · as of Aug 7, 2026
Ownership
Share classes
| Common Stock | 93.69% | |
| Common Stock | 6.31% |
| Institutions | 47.92% | 32,476,972 |
| Public float | 52.08% | 35,302,283 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 11
View all →| Insider | % of shares | Shares |
|---|---|---|
667, L.P.Director | — | — |
Amello JasonChief Financial Officer | — | — |
Baker Bros. Advisors (GP) LLCDirector | — | — |
Baker Bros. Advisors LPDirector | — | — |
Baker Brothers Life Sciences LPDirector | — | — |
Baker FelixDirector | — | — |
Baker JulianDirector | — | — |
Dworak LeidenSee Remarks | — | — |
Louis ChrystalChief Medical Officer | — | — |
MacBeath GavinCEOChief Executive Officer · Director | — | — |
Institutional holders 62
View all →| Holder | Value | % of shares |
|---|---|---|
| $8.02M | 11.83% | |
| $5.62M | 8.21% | |
| $2.81M | 4.11% | |
| $2.48M | 3.65% | |
| $1.79M | 2.63% | |
| $1.47M | 2.15% | |
| $1.38M | 2.01% | |
| $1.25M | 1.84% | |
| $1.22M | 1.78% | |
| $974.9K | 1.47% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common Stock | $1.07M | +1.1M +261.80% | 1,460,285 2.15% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Trim | Common Stock | $-837.0K | -854K -46.20% | 994,654 1.47% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | Common Stock | $563.4K | +558K +85.66% | 1,209,009 1.78% of shares | low |
| Q1 2026 as of | Bvf INC/IL 13F manager | Add | Common Stock | $341.6K | +338K +6.47% | 5,564,290 8.21% of shares | low |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | Add | Common Stock | $252.7K | +250K +360.32% | 319,587 0.47% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Add | Common Stock | $226.0K | +224K +19.61% | 1,364,783 2.01% of shares | low |
| Q3 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $223.6K | +45K +341.10% | 58,067 0.09% of shares | low |
| Q4 2025 as of | Militia Capital Partners, LP 13F manager | Exit | Common Stock | $-185.8K | -102K -100.00% | 0 | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TCRX | Common Stock | 89854M101 |